Dapk1 Mouse shRNA Plasmid (Locus ID 69635)

CAT#: TL504327

Dapk1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL504327A virus into HEK293 cells. TL504327A virus was prepared using lenti-shRNA TL504327A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL504327B virus into HEK293 cells. TL504327B virus was prepared using lenti-shRNA TL504327B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL504327C] virus into HEK293 cells. [TL504327C] virus was prepared using lenti-shRNA [TL504327C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL504327D] virus into HEK293 cells. [TL504327D] virus was prepared using lenti-shRNA [TL504327D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 69635
• Synonyms: D13Ucla1; DAP-Kinase
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol (34 ug/ml)
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: Dapk1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 69635). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: BC057317, BC060161, NM_001285917, NM_029653, NM_134062, NM_134062.1, NM_134062.2, NM_029653.1, NM_029653.2, NM_029653.3, NM_001285917.1, BC021490, BC026671, BC037483
• UniProt ID: Q80YE7
• Summary: Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing stress fiber formation in endothelial cells. Phosphorylates STX1A and significantly decreases its binding to STXBP1. Phosphorylates PRKD1 and regulates JNK signaling by binding and activating PRKD1 under oxidative stress. Phosphorylates BECN1, reducing its interaction with BCL2 and BCL2L1 and promoting the induction of autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating mTORC1 activity in a growth factor-dependent pathway. Phosphorylates RPS6, MYL9 and DAPK3 (By similarity). Acts as a signaling amplifier of NMDA receptors at extrasynaptic sites for mediating brain damage in stroke. Cerebral ischemia recruits DAPK1 into the NMDA receptor complex and it phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx through NMDA receptor channels, resulting in an irreversible neuronal death. Required together with DAPK3 for phosphorylation of RPL13A upon interferon-gamma activation which is causing RPL13A involvement in transcript-selective translation inhibition.[UniProtKB/Swiss-Prot Function]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).